Kombilipid (Olive Oil, Refined, Soya-Bean Oil Refined, Triglycerides, Medium Chain, Fish Oil, Rich In Omega-3-Ac)

The lipid components of Kombilipid—refined olive oil, soybean oil, medium‑chain triglycerides, and fish oil rich in omega‑3—are incorporated into plasma lipoproteins after infusion. They serve as an immediate energy source, supply essential fatty acids for cell membrane synthesis, and modulate inflammatory pathways, thereby supporting overall metabolic requirements.

The dose of Kombilipid is individualized and determined by the prescribing clinician based on the patient’s caloric needs, lipid tolerance, and laboratory parameters such as triglyceride levels. Healthcare professionals calculate the appropriate infusion rate and total daily lipid volume according to established parenteral nutrition protocols.

The safety of Kombilipid in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with obstetric specialists.

To order Kombilipid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with import documentation.

Kombilipid contains a balanced mix of long‑chain, medium‑chain, and omega‑3 rich fish oil triglycerides, offering a broader fatty‑acid profile than many standard emulsions that rely mainly on soybean or safflower oil. This composition may provide improved anti‑inflammatory effects and better lipid tolerance, though clinical choice depends on patient-specific factors and institutional protocols.

Kombilipid must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the emulsion to reach room temperature if required, and inspect for any signs of separation or discoloration. Follow aseptic techniques during preparation and infusion.

Kombilipid is administered intravenously as a sterile lipid emulsion, typically infused through a dedicated line or Y‑site connector as part of a total parenteral nutrition regimen. The infusion rate is set by the clinician based on prescribed lipid calories, and the product should be administered using a filter to remove potential particulates.

Serious risks include fat overload syndrome, severe hypertriglyceridaemia, anaphylactic reactions (especially in patients allergic to fish or soy), pulmonary lipid embolism, and hepatic dysfunction with prolonged use. Prompt monitoring of triglyceride levels, liver function tests, and clinical signs of allergy is essential to mitigate these risks.

Kombilipid is contraindicated in patients with known hypersensitivity to any of its lipid components (fish, soy, olive oil), those with severe hyperlipidaemia, disorders of fat metabolism, or a history of fat overload syndrome. It should also be used with caution in patients with compromised liver function or severe sepsis.